Cadilas arm receives 1 observation from USFDA for Ahmedabad plant

The USFDA had conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac Pharmaceuticals' facility from March 18 to 26.

from India Infoline News Service https://ift.tt/2JJ9gJb